Alzheimer’s Research Papers~ November 2002 ~ Beta Amyloid Blog
Lalonde R, Dumont M, Staufenbiel M, Sturchler-Pierrat C, Strazielle C. Spatial learning, exploration, anxiety, and motor coordination in female APP23 transgenic mice with the Swedish mutation. Brain Res. 2002 Nov 22;956(1):36-44.
Jo I, Im HM, Shin HJ, Won Cho K, Jung M, Kim SD, Kim Jeong J, Ahn Jo S. Serum deprivation increases the expression of low density lipoprotein receptor-related protein in primary cultured rat astrocytes. Biochem Biophys Res Commun. 2002 Nov 22;299(1):102-8.
Maynard CJ, Cappai R, Volitakis I, Cherny RA, White AR, Beyreuther K, Masters CL, Bush AI, Li QX. Overexpression of Alzheimer's disease amyloid-beta opposes the age-dependent elevations of brain copper and iron. J Biol Chem. 2002 Nov 22;277(47):44670-6.
Lammich S, Okochi M, Takeda M, Kaether C, Capell A, Zimmer AK, Edbauer D, Walter J, Steiner H, Haass C. Presenilin-dependent intramembrane proteolysis of CD44 leads to the liberation of its intracellular domain and the secretion of an Abeta-like peptide. J Biol Chem. 2002 Nov 22;277(47):44754-9.
Sterling J, Herzig Y, Goren T, Finkelstein N, Lerner D, Goldenberg W, Miskolczi I, Molnar S, Rantal F, Tamas T, Toth G, Zagyva A, Zekany A, Lavian G, Gross A, Friedman R, Razin M, Huang W, Krais B, Chorev M, Youdim MB, Weinstock M. Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease. J Med Chem. 2002 Nov 21;45(24):5260-79.
Hanger DP, Gibb GM, de Silva R, Boutajangout A, Brion JP, Revesz T, Lees AJ, Anderton BH. The complex relationship between soluble and insoluble tau in tauopathies revealed by efficient dephosphorylation and specific antibodies. FEBS Lett. 2002 Nov 20;531(3):538-42.
Hasegawa K, Ono K, Yamada M, Naiki H. Kinetic modeling and determination of reaction constants of Alzheimer's beta-amyloid fibril extension and dissociation using surface plasmon resonance. Biochemistry. 2002 Nov 19;41(46):13489-98.
Goux WJ. The conformations of filamentous and soluble tau associated with Alzheimer paired helical filaments. Biochemistry. 2002 Nov 19;41(46):13798-806.
Cottingham MG, Hollinshead MS, Vaux DJ. Amyloid fibril formation by a synthetic peptide from a region of human acetylcholinesterase that is homologous to the Alzheimer's amyloid-beta peptide. Biochemistry. 2002 Nov 19;41(46):13539-47.
Gottlieb S. Long term HRT may protect women from Alzheimer's disease. BMJ. 2002 Nov 16;325(7373):1130A.
Dodart JC, Bales KR, Johnstone EM, Little SP, Paul SM. Apolipoprotein E alters the processing of the beta-amyloid precursor protein in APP(V717F) transgenic mice. Brain Res. 2002 Nov 15;955(1-2):191-9.
Kalaria R. Similarities between Alzheimer's disease and vascular dementia. J Neurol Sci. 2002 Nov 15;203-204(C):29-34.
Bowler JV. The concept of vascular cognitive impairment. J Neurol Sci. 2002 Nov 15;203-204(C):11-5.
Salloway S, Gur T, Berzin T, Zipser B, Correia S, Hovanesian V, Fallon J, Kuo-Leblanc V, Glass D, Hulette C, Rosenberg C, Vitek M, Stopa E. Effect of APOE genotype on microvascular basement membrane in Alzheimer's disease. J Neurol Sci. 2002 Nov 15;203-204:183-7.
Frölich L, Klinger T, Berger FM. Treatment with donepezil in Alzheimer patients with and without cerebrovascular disease. J Neurol Sci. 2002 Nov 15;203-204(C):137-9.
Erkinjuntti T. Treatment options. The latest evidence with galantamine (Reminyl(R)). J Neurol Sci. 2002 Nov 15;203-204(C):125-30.
Gerlai R, Fitch T, Bales KR, Gitter BD. Behavioral impairment of APP(V717F) mice in fear conditioning: is it only cognition? Behav Brain Res. 2002 Nov 15;136(2):503-9.
Lojkowska W, Ryglewicz D, Jedrzejczak T, Sienkiewicz-Jarosz H, Minc S, Jakubowska T, Kozlowicz-Gudzinska I. SPECT as a diagnostic test in the investigation of dementia. J Neurol Sci. 2002 Nov 15;203-204(C):215-9.
Sheng JG, Price DL, Koliatsos VE. Disruption of corticocortical connections ameliorates amyloid burden in terminal fields in a transgenic model of Abeta amyloidosis. J Neurosci. 2002 Nov 15;22(22):9794-9. ,
Lazarov O, Lee M, Peterson DA, Sisodia SS. Evidence that synaptically released beta-amyloid accumulates as extracellular deposits in the hippocampus of transgenic mice. J Neurosci. 2002 Nov 15;22(22):9785-93.
Tuszynski MH, U HS, Alksne J, Bakay RA, Pay MM, Merrill D, Thal LJ. Growth factor gene therapy for Alzheimer disease. Neurosurg Focus. 2002 Nov 15;13(5):e5.
Hashiguchi M, Saito T, Hisanaga S, Hashiguchi T. Truncation of CDK5 activator p35 induces intensive phosphorylation of Ser202/Thr205 of human tau. J Biol Chem. 2002 Nov 15;277(46):44525-30.
Ishii K, Klunk WE, Arawaka S, Debnath ML, Furiya Y, Sahara N, Shoji S, Tamaoka A, Pettegrew JW, Mori H. Chrysamine G and its derivative reduce amyloid beta-induced neurotoxicity in mice. Neurosci Lett. 2002 Nov 15;333(1):5-8.
Santucci AC, Perez S. Multiple injections of thyrotropin releasing hormone fail to reverse learning and memory deficits in rats with lesions of the nucleus basalis of meynert. Behav Brain Res. 2002 Nov 15;136(2):433-8.
Nunomura A, Chiba S, Kosaka K, Takeda A, Castellani RJ, Smith MA, Perry G. Neuronal RNA oxidation is a prominent feature of dementia with Lewy bodies. Neuroreport. 2002 Nov 15;13(16):2035-9.
Gatta LB, Albertini A, Ravid R, Finazzi D. Levels of beta-secretase BACE and alpha-secretase ADAM10 mRNAs in Alzheimer hippocampus. Neuroreport. 2002 Nov 15;13(16):2031-3.
Yin KJ, Lee JM, Chen SD
Fath T, Eidenmüller J, Brandt R. Tau-mediated cytotoxicity in a pseudohyperphosphorylation model of Alzheimer's disease. J Neurosci. 2002 Nov 15;22(22):9733-41.
Kuwako K, Nishimura I, Uetsuki T, Saido TC, Yoshikawa K. Activation of calpain in cultured neurons overexpressing Alzheimer amyloid precursor protein. Brain Res Mol Brain Res. 2002 Nov 15;107(2):166-75.
Bonelli RM, Aschoff A, Jirikowski G. Cerebrospinal fluid tissue transglutaminase in vascular dementia. J Neurol Sci. 2002 Nov 15;203-204(C):207-9.
Scheinfeld MH, Ghersi E, Laky K, Fowlkes BJ, D'Adamio L. Processing of beta-amyloid precursor-like protein-1 and -2 by gamma-secretase regulates transcription. J Biol Chem. 2002 Nov 15;277(46):44195-201.
Lue LF, Walker DG. Modeling Alzheimer's disease immune therapy mechanisms: interactions of human postmortem microglia with antibody-opsonized amyloid beta peptide. J Neurosci Res. 2002 Nov 15;70(4):599-610.
Maeck L, Meller J, Otto M, Stiens G, Wiltfang J, Stoppe G. Abeta peptide(1-42), Tau protein and S-100B protein level in cerebrospinal fluid of three patients with primary progressive aphasia. Neurosci Lett. 2002 Nov 15;333(1):33-6.
Mubumbila V, Sutter A, Ptok U, Heun R, Quirin-Stricker C. Identification of a single nucleotide polymorphism in the choline acetyltransferase gene associated with Alzheimer's disease. Neurosci Lett. 2002 Nov 15;333(1):9-12. ,
Pratt RD. Patient populations in clinical trials of the efficacy and tolerability of donepezil in patients with vascular dementia. J Neurol Sci. 2002 Nov 15;203-204:57-65.
O'Brien J, Lilienfeld S. Relevant clinical outcomes in probable vascular dementia and Alzheimer's disease with cerebrovascular disease. J Neurol Sci. 2002 Nov 15;203-204(C):41-8.
Schmidtke K, Hüll M. Neuropsychological differentiation of small vessel disease, Alzheimer's disease and mixed dementia. J Neurol Sci. 2002 Nov 15;203-204(C):17-22.
Borroni B, Akkawi N, Martini G, Colciaghi F, Prometti P, Rozzini L, Di Luca M, Lenzi GL, Romanelli G, Caimi L, Padovani A. Microvascular damage and platelet abnormalities in early Alzheimer's disease. J Neurol Sci. 2002 Nov 15;203-204(C):189-93.
Traykov L, Rigaud AS
Jellinger KA. The pathology of ischemic-vascular dementia. An update. J Neurol Sci. 2002 Nov 15;203-204(C):153-7.
Grantham C, Geerts H. The rationale behind cholinergic drug treatment for dementia related to cerebrovascular disease. J Neurol Sci. 2002 Nov 15;203-204(C):131-6.
Bowirrat A, Friedland RP, Korczyn AD. Vascular dementia among elderly Arabs in Wadi Ara. J Neurol Sci. 2002 Nov 15;203-204(C):73-6.
Cecchi C, Fiorillo C, Sorbi S, Latorraca S, Nacmias B, Bagnoli S, Nassi P, Liguri G. Oxidative stress and reduced antioxidant defenses in peripheral cells from familial Alzheimer's patients. Free Radic Biol Med. 2002 Nov 15;33(10):1372-9.
Curtain CC, Ali FE, Smith DG, Bush AI, Masters CL, Barnham KJ. Metal ions, pH and cholesterol regulate the interactions of Alzheimer's disease amyloid-b peptide with membrane lipid. J Biol Chem. 2002 Nov 14;
Varner AE. Antioxidants and risk of Alzheimer disease. JAMA. 2002 Nov 13;288(18):2265;
Stephenson J. The world in medicine: Alzheimer disease vaccine. JAMA. 2002 Nov 13;288(18):2257.
Brenner S. Antioxidants and risk of Alzheimer disease. JAMA. 2002 Nov 13;288(18):2265;
Morris MC, Evans DA, Bienias JL, Tangney CC, Bennett DA, Aggarwal N, Wilson RS, Scherr PA. Antioxidants and risk of Alzheimer disease. JAMA. 2002 Nov 13;288(18):2265-6.
Engelhart MJ, Breteler MM. Antioxidants and risk of Alzheimer disease. JAMA. 2002 Nov 13;288(18):2265-6.
Gao L, Gabriel C, Lavoie T, Ye S. An Improved RSP Method to Detect HpaI Polymorphism in the Apolipoprotein C-1 Gene Promoter. BMC Med Genet. 2002 Nov 12;3(1):13.
Atamna H, Killilea DW, Killilea AN, Ames BN. Heme deficiency may be a factor in the mitochondrial and neuronal decay of aging. Proc Natl Acad Sci U S A. 2002 Nov 12;99(23):14807-12.
Dubois B, Touchon J, Portet F, Ousset PJ, Vellas B, Michel B. ["The 5 words": a simple and sensitive test for the diagnosis of Alzheimer's disease] Presse Med. 2002 Nov 9;31(36):1696-9.
Ma SL, Ng HK, Baum L, Pang JC, Chiu HF, Woo J, Tang NL, Lam LC. Low-density lipoprotein receptor-related protein 8 (apolipoprotein E receptor 2) gene polymorphisms in Alzheimer's disease. Neurosci Lett. 2002 Nov 8;332(3):216-8. ,
Infante J, Llorca J, Rodero L, Palacio E, Berciano J, Combarros O. Polymorphism at codon 174 of the prion-like protein gene is not associated with sporadic Alzheimer's disease. Neurosci Lett. 2002 Nov 8;332(3):213-5. ,
Zhu X, Yu QS, Cutler RG, Culmsee CW, Holloway HW, Lahiri DK, Mattson MP, Greig NH. Novel p53 inactivators with neuroprotective action: syntheses and pharmacological evaluation of 2-imino-2,3,4,5,6,7-hexahydrobenzothiazole and 2-imino-2,3,4,5,6,7-hexahydrobenzoxazole derivatives. J Med Chem. 2002 Nov 7;45(23):5090-7.
Kairane C, Roots K, Uusma T, Bogdanovic N, Karelson E, Kõks S, Zilmer M. Regulation of the frontocortical sodium pump by Na+ in Alzheimer's disease: difference from the age-matched control but similarity to the rat model. FEBS Lett. 2002 Nov 6;531(2):241-4.
Resnick SM, Henderson VW. Hormone therapy and risk of Alzheimer disease: a critical time. JAMA. 2002 Nov 6;288(17):2170-2.
Zandi PP, Carlson MC, Plassman BL, Welsh-Bohmer KA, Mayer LS, Steffens DC , Breitner JC, Cache County
de Jong D, Jansen RW, Verbeek MM, Kremer HP. [In Process Citation] Ned Tijdschr Geneeskd. 2002 Nov 2;146(44):2074-8.
Huang HM, Kuo YM, Ou HC, Lin CC, Chuo LJ. Apolipoprotein E polymorphism in various dementias in Taiwan Chinese population. J Neural Transm. 2002 Nov;109(11):1415-21.
Neugroschl J, Davis KL. Biological markers in Alzheimer disease. Am J Geriatr Psychiatry. 2002 Nov-Dec;10(6):660-77.
Selkoe DJ. Deciphering the genesis and fate of amyloid beta-protein yields novel therapies for Alzheimer disease. J Clin Invest. 2002 Nov 1;110(10):1375-81.
Honda N, Machida K, Hosono M, Matsumoto T, Matsuda H, Oshima M, Koizumi K, Kosuda S, Momose T, Mori Y, Hashimoto J, Shimizu Y. Interobserver variation in diagnosis of dementia by brain perfusion SPECT. Radiat Med. 2002 Nov-Dec;20(6):281-9.
Spiegel R. [Rivastigmine: a review of its clinical effectiveness] Rev Neurol. 2002 Nov 1;35(9):859-69.
Kaufer D. [Treatment of neuropsychiatric symptoms in Alzheimer s disease] Rev Neurol. 2002 Nov 1;35(9):846-50.
Smith-Gamble V, Baiyewu O, Perkins AJ, Gureje O, Hall KS, Ogunniyi A, Hui SL, Hendrie HC. Informant reports of changes in personality predict dementia in a population-based study of elderly african americans and yoruba. Am J Geriatr Psychiatry. 2002 Nov-Dec;10(6):724-32.
Ahmed S, Mozley PD, Potter WZ. Biomarkers in psychotropic drug development. Am J Geriatr Psychiatry. 2002 Nov-Dec;10(6):678-86.
Town T, Vendrame M, Patel A, Poetter D, Delledonne A, Mori T, Smeed R, Crawford F, Klein T, Tan J, Mullan M. Reduced Th1 and enhanced Th2 immunity after immunization with Alzheimer's beta-amyloid(1-42). J Neuroimmunol. 2002 Nov 1;132(1-2):49-59.
Granholm AC, Ford KA, Hyde LA, Bimonte HA, Hunter CL, Nelson M, Albeck D, Sanders LA, Mufson EJ, Crnic LS. Estrogen restores cognition and cholinergic phenotype in an animal model of Down syndrome. Physiol Behav. 2002 Nov;77(2-3):371-85.
Larson E. Galantamine improved cognition and global functioning in vascular dementia or Alzheimer disease with cerebrovascular disease. ACP J Club. 2002 Nov-Dec;137(3):102.
None None. Hormone replacement therapy and incidence of Alzheimer disease in older women: the cache county study. JAMA 2002 Nov 6;288(17):2123-9. 2002 Nov;288(17):2123-9. Abstract
Kovács GG, Trabattoni G, Hainfellner JA, Ironside JW, Knight RS, Budka H. Mutations of the prion protein gene phenotypic spectrum. J Neurol. 2002 Nov;249(11):1567-82.
Dickson DW, Bergeron C, Chin SS, Duyckaerts C, Horoupian D, Ikeda K, Jellinger K, Lantos PL, Lippa CF, Mirra SS, Tabaton M, Vonsattel JP, Wakabayashi K, Litvan I, Office of Rare Diseases of the National Institutes of Health. Office of Rare Diseases neuropathologic criteria for corticobasal degeneration. J Neuropathol Exp Neurol. 2002 Nov;61(11):935-46.
Biernat J, Wu YZ, Timm T, Zheng-Fischhöfer Q, Mandelkow E, Meijer L, Mandelkow EM. Protein Kinase MARK/PAR-1 Is Required for Neurite Outgrowth and Establishment of Neuronal Polarity. Mol Biol Cell. 2002 Nov;13(11):4013-28.
Lange KL, Bondi MW, Salmon DP, Galasko D, Delis DC, Thomas RG, Thal LJ. Decline in verbal memory during preclinical Alzheimer's disease: examination of the effect of APOE genotype. J Int Neuropsychol Soc. 2002 Nov;8(7):943-55. ,
Kantarci K, Smith GE, Ivnik RJ, Petersen RC, Boeve BF, Knopman DS, Tangalos EG, Jack CR. 1H magnetic resonance spectroscopy, cognitive function, and apolipoprotein E genotype in normal aging, mild cognitive impairment and Alzheimer's disease. J Int Neuropsychol Soc. 2002 Nov;8(7):934-42.
Cook L, Brayne CE, Easton D, Evans JG, Xuereb J, Cairns NJ , Rubinsztein DC
Hur K, Kim JI, Choi SI, Choi EK, Carp RI, Kim YS. The pathogenic mechanisms of prion diseases. Mech Ageing Dev. 2002 Nov;123(12):1637-47.
Bishop GM, Robinson SR. The amyloid hypothesis: let sleeping dogmas lie? Neurobiol Aging. 2002 Nov-Dec;23(6):1101-5.
Holtzman DM. Abeta conformational change is central to Alzheimer's disease. Neurobiol Aging. 2002 Nov-Dec;23(6):1085-8.
Robinson SR, Bishop GM. Abeta as a bioflocculant: implications for the amyloid hypothesis of Alzheimer's disease. Neurobiol Aging. 2002 Nov-Dec;23(6):1051-72.
Karlawish JH, Clark CM. Addressing the challenges of transforming laboratory advances into Alzheimer's Disease treatments. Neurobiol Aging. 2002 Nov-Dec;23(6):1043-9.
Lee VM. Amyloid binding ligands as Alzheimer's disease therapies. Neurobiol Aging. 2002 Nov-Dec;23(6):1039-42.
Bush AI. Metal complexing agents as therapies for Alzheimer's disease. Neurobiol Aging. 2002 Nov-Dec;23(6):1031-8.
Williams JH, Pereira EA, Budge MM, Bradley KM. Minimal hippocampal width relates to plasma homocysteine in community-dwelling older people. Age Ageing. 2002 Nov;31(6):440-4.
Pratt RD, Perdomo CA, Surick IW, Ieni JR. Donepezil: tolerability and safety in Alzheimer's disease. Int J Clin Pract. 2002 Nov;56(9):710-7.
Beach TG. Muscarinic agonists as preventative therapy for Alzheimer's disease. Curr Opin Investig Drugs. 2002 Nov 1;3(11):1633-6.
Lilienfeld S, Kurz A. Broad therapeutic benefits in patients with probable vascular dementia or Alzheimer's disease with cerebrovascular disease treated with galantamine. Ann N Y Acad Sci. 2002 Nov;977:487-92.
Kurz A. A novel treatment for patients with Alzheimer's disease and with vascular dementia. Ann N Y Acad Sci. 2002 Nov;977:476-81.
Kondo M, Imahori Y, Mori S, Nakajima K. Inositol phospholipid metabolism in Alzheimer's disease: a positron emission tomographic study. Ann N Y Acad Sci. 2002 Nov;977:416-22.
Yanagisawa K, Matsuzaki K. Cholesterol-dependent aggregation of amyloid beta-protein. Ann N Y Acad Sci. 2002 Nov;977:384-6.
Kudo T, Katayama T, Imaizumi K, Yasuda Y, Yatera M, Okochi M, Tohyama M, Takeda M. The unfolded protein response is involved in the pathology of Alzheimer's disease. Ann N Y Acad Sci. 2002 Nov 1;977:349-55.
Casoli T, Di Stefano G, Delfino A, Solazzi M, Fattoretti P, Bertoni-Freddari C, Guidi M, Scarpino O, Giunta S, Galeazzi L. Beta-amyloid fragment 25-35 selectively damages platelets from patients with Alzheimer's disease. Ann N Y Acad Sci. 2002 Nov;977:296-302.
Van Nostrand WE, Melchor JP, Romanov G, Zeigler K, Davis J. Pathogenic effects of cerebral amyloid angiopathy mutations in the amyloid beta-protein precursor. Ann N Y Acad Sci. 2002 Nov;977:258-65.
Kenny RA, Kalaria R, Ballard C. Neurocardiovascular instability in cognitive impairment and dementia. Ann N Y Acad Sci. 2002 Nov;977:183-95.
Otsuka M, Yamaguchi K, Ueki A. Similarities and differences between Alzheimer's disease and vascular dementia from the viewpoint of nutrition. Ann N Y Acad Sci. 2002 Nov;977:155-61.
Dantoine TF, Debord J, Merle L, Lacroix-Ramiandrisoa H, Bourzeix L, Charmes JP. Paraoxonase 1 activity: a new vascular marker of dementia? Ann N Y Acad Sci. 2002 Nov;977:96-101.
Skoog I, Gustafson D. Hypertension and related factors in the etiology of Alzheimer's disease. Ann N Y Acad Sci. 2002 Nov 1;977:29-36.
Karelson E, Mahlapuu R, Zilmer M, Soomets U, Bogdanovic N, Langel U. Possible signaling by glutathione and its novel analogue through potent stimulation of fontocortical G proteins in normal aging and in Alzheimer's disease. Ann N Y Acad Sci. 2002 Nov;973:537-40.
Lahiri DK, Alley GM, Ge YW, Du Y. Functional characterization of the 5'-regulatory region of the murine apolipoprotein gene. Ann N Y Acad Sci. 2002 Nov;973:340-4.
Jang JH, Surh YJ. beta-Amyloid induces oxidative DNA damage and cell death through activation of c-Jun N terminal kinase. Ann N Y Acad Sci. 2002 Nov;973:228-36.
Vamvakidès A. [Mechanism of action of tetrahydro-N, N-dimethyl-5, 5-diphenyl-3-furanemethanamine, a putative nootropic, anti-epileptic and antidepressant compound] Ann Pharm Fr. 2002 Nov;60(6):415-22.
Kölsch H, Rao ML. Neuroprotective effects of estradiol-17beta: implications for psychiatric disorders. Arch Women Ment Health. 2002 Nov;5(3):105-10.
Rohn TT, Rissman RA, Davis MC, Kim YE, Cotman CW, Head E. Caspase-9 activation and caspase cleavage of tau in the Alzheimer's disease brain. Neurobiol Dis. 2002 Nov 1;11(2):341-54.
Kumar-Singh S, Julliams A, Nuydens R, Ceuterick C, Labeur C, Serneels S, Vennekens K, Van Osta P, Geerts H, De Strooper B, van Broeckhoven C. In vitro studies of Flemish, Dutch, and wild-type beta-amyloid provide evidence for two-staged neurotoxicity. Neurobiol Dis. 2002 Nov;11(2):330-40.
Poduslo JF, Wengenack TM, Curran GL, Wisniewski T, Sigurdsson EM, Macura SI, Borowski BJ, Jack CR. Molecular targeting of Alzheimer's amyloid plaques for contrast-enhanced magnetic resonance imaging. Neurobiol Dis. 2002 Nov;11(2):315-29.
Picklo MJ, Montine TJ, Amarnath V, Neely MD. Carbonyl toxicology and Alzheimer's disease. Toxicol Appl Pharmacol. 2002 Nov 1;184(3):187-97.
Gray-Vickrey P. Advances in Alzheimer's disease. Nursing. 2002 Nov;32(11 Pt 1):64.
Zekry D, Duyckaerts C, Belmin J, Geoffre C, Moulias R, Hauw JJ. Alzheimer's disease and brain infarcts in the elderly Agreement with neuropathology. J Neurol. 2002 Nov;249(11):1529-34.
Bigler ED, Tate DF, Miller MJ, Rice SA, Hessel CD, Earl HD, Tschanz JT, Plassman B, Welsh-Bohmer KA. Dementia, asymmetry of temporal lobe structures, and apolipoprotein E genotype: relationships to cerebral atrophy and neuropsychological impairment. J Int Neuropsychol Soc. 2002 Nov;8(7):925-33.
Xu G, Meyer JS, Thornby J, Chowdhury M, Quach M. Screening for mild cognitive impairment (MCI) utilizing combined mini-mental-cognitive capacity examinations for identifying dementia prodromes. Int J Geriatr Psychiatry. 2002 Nov;17(11):1027-33.
Le Y, Murphy PM, Wang JM. Formyl-peptide receptors revisited. Trends Immunol. 2002 Nov;23(11):541-8.
Micchelli CA, Esler WP, Kimberly WT, Jack C, Berezovska O, Kornilova A, Hyman BT, Perrimon N, Wolfe MS. g-Secretase/presenilin inhibitors for Alzheimer's disease phenocopy Notch mutations in Drosophila. FASEB J. 2002 Nov 1;
Crescenzi O, Tomaselli S, Guerrini R, Salvadori S, D'Ursi AM, Temussi PA, Picone D. Solution structure of the Alzheimer amyloid beta-peptide (1-42) in an apolar microenvironment. Similarity with a virus fusion domain. Eur J Biochem. 2002 Nov 1;269(22):5642-8.
McGeer PL, McGeer EG. The possible role of complement activation in Alzheimer disease. Trends Mol Med. 2002 Nov;8(11):519-23.
Morihara T, Chu T, Ubeda O, Beech W, Cole GM. Selective inhibition of Abeta42 production by NSAID R-enantiomers. J Neurochem. 2002 Nov;83(4):1009-12.
Allen B, Ingram E, Takao M, Smith MJ, Jakes R, Virdee K, Yoshida H, Holzer M, Craxton M, Emson PC, Atzori C, Migheli A, Crowther RA, Ghetti B, Spillantini MG, Goedert M. Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J Neurosci. 2002 Nov 1;22(21):9340-51.
Dechant G, Barde YA. The neurotrophin receptor p75(NTR): novel functions and implications for diseases of the nervous system. Nat Neurosci. 2002 Nov;5(11):1131-6.
Citron M. Alzheimer's disease: treatments in discovery and development. Nat Neurosci. 2002 Nov;5 Suppl:1055-7.
Kemp JA, McKernan RM. NMDA receptor pathways as drug targets. Nat Neurosci. 2002 Nov;5 Suppl:1039-42.
Adunsky A, Chesnin V, Davidson M, Gerber Y, Alexander K, Haratz D. A cross-sectional study of lipids and ApoC levels in Alzheimer's patients with and without cardiovascular disease. J Gerontol A Biol Sci Med Sci. 2002 Nov;57(11):M757-61.
Schulz S, Schagdarsurengin U, Greiser P, Birkenmeier G, Müller-Werdan U, Hagemann M, Riemann D, Werdan K, Gläser C. The LDL receptor-related protein (LRP1/A2MR) and coronary atherosclerosis--novel genomic variants and functional consequences. Hum Mutat. 2002 Nov;20(5):404.
Tanahashi H, Asada T, Tabira T. c954C-->T polymorphism in the Fe65L2 gene is associated with early-onset Alzheimer's disease. Ann Neurol. 2002 Nov;52(5):691-3.
Feinstein D, Heneka M, Gavrilyuk V, Russo C, Weinberg G, Galea E. Noradrenergic regulation of inflammatory gene expression in brain. Neurochem Int. 2002 Nov;41(5):357.
Seo JH, Rah JC, Choi SH, Shin JK, Min K, Kim HS, Park CH, Kim S, Kim EM, Lee SH, Lee S, Suh SW, Suh YH. Alpha-synuclein regulates neuronal survival via Bcl-2 family expression and PI3/Akt kinase pathway. FASEB J. 2002 Nov;16(13):1826-8.
Hock C, Konietzko U, Papassotiropoulos A, Wollmer A, Streffer J, Von Rotz RC, Davey G, Moritz E, Nitsch RM. Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease. Nat Med. 2002 Nov;8(11):1270-5.
Bowen RL, Smith MA, Harris PL, Kubat Z, Martins RN, Castellani RJ, Perry G, Atwood CS. Elevated luteinizing hormone expression colocalizes with neurons vulnerable to Alzheimer's disease pathology. J Neurosci Res. 2002 Nov 1;70(3):514-8.
Kubo T, Nishimura S, Kumagae Y, Kaneko I. In vivo conversion of racemized beta-amyloid ([D-Ser 26]A beta 1-40) to truncated and toxic fragments ([D-Ser 26]A beta 25-35/40) and fragment presence in the brains of Alzheimer's patients. J Neurosci Res. 2002 Nov 1;70(3):474-83.
Colangelo V, Schurr J, Ball MJ, Pelaez RP, Bazan NG, Lukiw WJ. Gene expression profiling of 12633 genes in Alzheimer hippocampal CA1: transcription and neurotrophic factor down-regulation and up-regulation of apoptotic and pro-inflammatory signaling. J Neurosci Res. 2002 Nov 1;70(3):462-73.
Teter B, Ashford JW. Neuroplasticity in Alzheimer's disease. J Neurosci Res. 2002 Nov 1;70(3):402-37.
Morishima-Kawashima M, Ihara Y. Alzheimer's disease: beta-Amyloid protein and tau. J Neurosci Res. 2002 Nov 1;70(3):392-401.
Rutten BP, Steinbusch HW, Korr H, Schmitz C. Antioxidants and Alzheimer's disease: from bench to bedside (and back again). Curr Opin Clin Nutr Metab Care. 2002 Nov;5(6):645-51.
Richardson RL, Kim EM, Shephard RA, Gardiner T, Cleary J, O'Hare E. Behavioural and histopathological analyses of ibuprofen treatment on the effect of aggregated Abeta(1-42) injections in the rat. Brain Res. 2002 Nov 1;954(1):1-10.
Matsuda H, Kanetaka H, Ohnishi T, Asada T, Imabayashi E, Nakano S, Katoh A, Tanaka F. Brain SPET abnormalities in Alzheimer's disease before and after atrophy correction. Eur J Nucl Med Mol Imaging. 2002 Nov;29(11):1502-5.
Varrone A, Pappatà S, Caracò C, Soricelli A, Milan G, Quarantelli M, Alfano B, Postiglione A, Salvatore M. Voxel-based comparison of rCBF SPET images in frontotemporal dementia and Alzheimer's disease highlights the involvement of different cortical networks. Eur J Nucl Med Mol Imaging. 2002 Nov;29(11):1447-54.
Garrido GE, Furuie SS, Buchpiguel CA, Bottino CM, Almeida OP, Cid CG, Camargo CH, Castro CC, Glabus MF, Busatto GF. Relation between medial temporal atrophy and functional brain activity during memory processing in Alzheimer's disease: a combined MRI and SPECT study. J Neurol Neurosurg Psychiatry. 2002 Nov;73(5):508-16.
Burns A. Meaningful treatment outcomes in Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2002 Nov;73(5):471-2.
Baron JC. Hippocampal atrophy and neocortical dysfunction in early Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2002 Nov;73(5):470-1.
Matsushita S, Arai H, Okamura N, Ohmori T, Takasugi K, Matsui T, Maruyama M, Iwatsubo T, Higuchi S. Clinical and biomarker investigation of a patient with a novel presenilin-1 mutation (A431V) in the mild cognitive impairment stage of Alzheimer's disease. Biol Psychiatry. 2002 Nov 1;52(9):907-10. ,
Smith MA, Casadesus G, Joseph JA, Perry G. Amyloid-beta and tau serve antioxidant functions in the aging and Alzheimer brain. Free Radic Biol Med. 2002 Nov 1;33(9):1194-9.
Hallegua DS, Weisman MH. Potential therapeutic uses of interleukin 1 receptor antagonists in human diseases. Ann Rheum Dis. 2002 Nov;61(11):960-7.
Cameron A, Rosenfeld J. Nutritional issues and supplements in amyotrophic lateral sclerosis and other neurodegenerative disorders. Curr Opin Clin Nutr Metab Care. 2002 Nov;5(6):631-43.
Brownlees J, Ackerley S, Grierson AJ, Jacobsen NJ, Shea K, Anderton BH, Leigh PN, Shaw CE, Miller CC. Charcot-Marie-Tooth disease neurofilament mutations disrupt neurofilament assembly and axonal transport. Hum Mol Genet. 2002 Nov 1;11(23):2837-44.
Rogers J, Strohmeyer R, Kovelowski CJ, Li R. Microglia and inflammatory mechanisms in the clearance of amyloid beta peptide. Glia. 2002 Nov;40(2):260-9.
Eikelenboom P, Bate C, van Gool WA, Hoozemans JJ, Rozemuller JM, Veerhuis R, Williams A. Neuroinflammation in Alzheimer's disease and prion disease. Glia. 2002 Nov;40(2):232-9.
Streit WJ. Microglia as neuroprotective, immunocompetent cells of the CNS. Glia. 2002 Nov;40(2):133-9.
Tabira T, Chui de H, Nakayama H, Kuroda S, Shibuya M. Alzheimer's disease with spastic paresis and cotton wool type plaques. J Neurosci Res. 2002 Nov 1;70(3):367-72.
Wen GY, Yang SY, Kaczmarski W, He XY, Pappas KS. Presence of hydroxysteroid dehydrogenase type 10 in amyloid plaques (APs) of Hsiao's APP-Sw transgenic mouse brains, but absence in APs of Alzheimer's disease brains. Brain Res. 2002 Nov 1;954(1):115-22.
Ono K, Hasegawa K, Yamada M, Naiki H. Nicotine breaks down preformed Alzheimer's beta-amyloid fibrils in vitro. Biol Psychiatry. 2002 Nov 1;52(9):880-6.
Monnier V, Girardot F, Audin W, Tricoire H. Control of oxidative stress resistance by IP3 kinase in Drosophila melanogaster. Free Radic Biol Med. 2002 Nov 1;33(9):1250-9.
van Leeuwen F, Gerez L, Benne R, Hol E. +1 Proteins and aging. Int J Biochem Cell Biol. 2002 Nov;34(11):1502.
Nakagami Y, Nishimura S, Murasugi T, Kaneko I, Meguro M, Marumoto S, Kogen H, Koyama K, Oda T. A novel beta-sheet breaker, RS-0406, reverses amyloid beta-induced cytotoxicity and impairment of long-term potentiation in vitro. Br J Pharmacol. 2002 Nov;137(5):676-82.
Koo EH. The beta-amyloid precursor protein (APP) and Alzheimer's disease: does the tail wag the dog? Traffic. 2002 Nov;3(11):763-70.
Iwata N, Takaki Y, Fukami S, Tsubuki S, Saido TC. Region-specific reduction of A beta-degrading endopeptidase, neprilysin, in mouse hippocampus upon aging. J Neurosci Res. 2002 Nov 1;70(3):493-500.
Park CH, Choi SH, Koo JW, Seo JH, Kim HS, Jeong SJ, Suh YH. Novel cognitive improving and neuroprotective activities of Polygala tenuifolia Willdenow extract, BT-11. J Neurosci Res. 2002 Nov 1;70(3):484-92.
Shimizu T, Fukuda H, Murayama S, Izumiyama N, Shirasawa T. Isoaspartate formation at position 23 of amyloid beta peptide enhanced fibril formation and deposited onto senile plaques and vascular amyloids in Alzheimer's disease. J Neurosci Res. 2002 Nov 1;70(3):451-61.
Abe T, Tohgi H, Isobe C, Murata T, Sato C. Remarkable increase in the concentration of 8-hydroxyguanosine in cerebrospinal fluid from patients with Alzheimer's disease. J Neurosci Res. 2002 Nov 1;70(3):447-50. ,
Niikura T, Hashimoto Y, Tajima H, Nishimoto I. Death and survival of neuronal cells exposed to Alzheimer's insults. J Neurosci Res. 2002 Nov 1;70(3):380-91.
Citron M. Beta-secretase as a target for the treatment of Alzheimer's disease. J Neurosci Res. 2002 Nov 1;70(3):373-9.
Yanagisawa K. Cholesterol and pathological processes in Alzheimer's disease. J Neurosci Res. 2002 Nov 1;70(3):361-6.
Castellani R, Hirai K, Aliev G, Drew KL, Nunomura A, Takeda A, Cash AD, Obrenovich ME, Perry G, Smith MA. Role of mitochondrial dysfunction in Alzheimer's disease. J Neurosci Res. 2002 Nov 1;70(3):357-60.
Watson JB, Khorasani H, Persson A, Huang KP, Huang FL, O'Dell TJ. Age-related deficits in long-term potentiation are insensitive to hydrogen peroxide: coincidence with enhanced autophosphorylation of Ca2+/calmodulin-dependent protein kinase II. J Neurosci Res. 2002 Nov 1;70(3):298-308.
Kihara T, Shimohama S, Sawada H, Honda K, Nakamizo T, Kanki R, Yamashita H, Akaike A. Protective effect of dopamine D2 agonists in cortical neurons via the phosphatidylinositol 3 kinase cascade. J Neurosci Res. 2002 Nov 1;70(3):274-82.
Mori N, Morii H. SCG10-related neuronal growth-associated proteins in neural development, plasticity, degeneration, and aging. J Neurosci Res. 2002 Nov 1;70(3):264-73.
Dhandapani KM, Brann DW. Protective effects of estrogen and selective estrogen receptor modulators in the brain. Biol Reprod. 2002 Nov;67(5):1379-85.
Milhavet O, Martindale JL, Camandola S, Chan SL, Gary DS, Cheng A, Holbrook NJ, Mattson MP. Involvement of Gadd153 in the pathogenic action of presenilin-1 mutations. J Neurochem. 2002 Nov;83(3):673-81.
Bahr BA, Bendiske J. The neuropathogenic contributions of lysosomal dysfunction. J Neurochem. 2002 Nov;83(3):481-9.
Inestrosa N, De Ferrari G, Garrido J, Alvarez A, Olivares G, Barri;a M, Bronfman M, Chacón M. Wnt signaling involvement in beta-amyloid-dependent neurodegeneration. Neurochem Int. 2002 Nov;41(5):341.
Klein WL. Abeta toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets. Neurochem Int. 2002 Nov;41(5):345-52.
Laferla FM. Calcium dyshomeostasis and intracellular signalling in Alzheimer's disease. Nat Rev Neurosci. 2002 Nov;3(11):862-72.
Wolfe MS. Therapeutic strategies for Alzheimer's disease. Nat Rev Drug Discov. 2002 Nov;1(11):859-66.
Weill-Engerer S, David JP, Sazdovitch V, Liere P, Eychenne B, Pianos A, Schumacher M, Delacourte A, Baulieu EE, Akwa Y. Neurosteroid quantification in human brain regions: comparison between Alzheimer's and nondemented patients. J Clin Endocrinol Metab. 2002 Nov;87(11):5138-43.
Dante S, Hauss T, Dencher NA. Beta-amyloid 25 to 35 is intercalated in anionic and zwitterionic lipid membranes to different extents. Biophys J. 2002 Nov;83(5):2610-6.
Takahashi RH, Milner TA, Li F, Nam EE, Edgar MA, Yamaguchi H, Beal MF, Xu H, Greengard P, Gouras GK. Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology. Am J Pathol. 2002 Nov;161(5):1869-79.
DeTure M, Ko LW, Easson C, Yen SH. Tau assembly in inducible transfectants expressing wild-type or FTDP-17 tau. Am J Pathol. 2002 Nov;161(5):1711-22.
Desgranges B, Baron JC, Giffard B, Chételat G, Lalevée C, Viader F, de la Sayette V, Eustache F. The neural basis of intrusions in free recall and cued recall: a PET study in Alzheimer's disease. Neuroimage. 2002 Nov;17(3):1658-64.
Prvulovic D, Hubl D, Sack AT, Melillo L, Maurer K, Frölich L, Lanfermann H, Zanella FE, Goebel R, Linden DE, Dierks T. Functional imaging of visuospatial processing in Alzheimer's disease. Neuroimage. 2002 Nov;17(3):1403-14.
Soonawala D, Amin T, Ebmeier KP, Steele JD, Dougall NJ, Best J, Migneco O, Nobili F, Scheidhauer K. Statistical parametric mapping of (99m)Tc-HMPAO-SPECT images for the diagnosis of Alzheimer's disease: normalizing to cerebellar tracer uptake. Neuroimage. 2002 Nov;17(3):1193-202.
Kovacevic N, Lobaugh NJ, Bronskill MJ, Levine B, Feinstein A, Black SE. A robust method for extraction and automatic segmentation of brain images. Neuroimage. 2002 Nov;17(3):1087-100.
Sherwin BB. Estrogen and cognitive aging in women. Trends Pharmacol Sci. 2002 Nov;23(11):527-34.
Haass C. New hope for Alzheimer disease vaccine. Nat Med. 2002 Nov;8(11):1195-6.
Fleming JS, Kemp PM, Bolt L, Goatman KA. Measurement of cerebral perfusion volume and 99mTc-HMPAO uptake using SPECT in controls and patients with Alzheimer's disease. Nucl Med Commun. 2002 Nov;23(11):1057-64.
Eimer S, Lakowski B, Donhauser R, Baumeister R. Loss of spr-5 bypasses the requirement for the C.elegans presenilin sel-12 by derepressing hop-1. EMBO J. 2002 Nov 1;21(21):5787-96.
Pietrzik CU, Busse T, Merriam DE, Weggen S, Koo EH. The cytoplasmic domain of the LDL receptor-related protein regulates multiple steps in APP processing. EMBO J. 2002 Nov 1;21(21):5691-700.
Fändrich M, Dobson CM. The behaviour of polyamino acids reveals an inverse side chain effect in amyloid structure formation. EMBO J. 2002 Nov 1;21(21):5682-90.
Mecocci P, Grossi E, Buscema M, Intraligi M, Savarè R, Rinaldi P, Cherubini A, Senin U. Use of artificial networks in clinical trials: a pilot study to predict responsiveness to donepezil in Alzheimer's disease. J Am Geriatr Soc. 2002 Nov;50(11):1857-60.
Rensink AA, Gellekink H, Otte-Höller I, Ten Donkelaar HJ, de Waal RM, Verbeek MM, Kremer B. Expression of the cytokine leukemia inhibitory factor and pro-apoptotic insulin-like growth factor binding protein-3 in Alzheimer's disease. Acta Neuropathol (Berl). 2002 Nov;104(5):525-33.
Holzer M, Gärtner U, Stöbe A, Härtig W, Gruschka H, Brückner MK, Arendt T. Inverse association of Pin1 and tau accumulation in Alzheimer's disease hippocampus. Acta Neuropathol (Berl). 2002 Nov;104(5):471-81.
Mori F, Hayashi S, Yamagishi S, Yoshimoto M, Yagihashi S, Takahashi H, Wakabayashi K. Pick's disease: alpha- and beta-synuclein-immunoreactive Pick bodies in the dentate gyrus. Acta Neuropathol (Berl). 2002 Nov;104(5):455-61.
Wilcock G, Möbius HJ, Stöffler A, MMM 500 group. A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol. 2002 Nov;17(6):297-305.
Blaizot AX, Meguro K, Millien I, Baron JC, Chavoix C. Correlations between visual recognition memory and neocortical and hippocampal glucose metabolism after bilateral rhinal cortex lesions in the baboon: implications for Alzheimer's disease. J Neurosci. 2002 Nov 1;22(21):9166-70.
Tan J, Town T, Abdullah L, Wu Y, Placzek A, Small B, Kroeger J, Crawford F, Richards D, Mullan M. CD45 isoform alteration in CD4+ T cells as a potential diagnostic marker of Alzheimer's disease. J Neuroimmunol. 2002 Nov;132(1-2):164-72.
Kertesz A. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomized trial. Curr Neurol Neurosci Rep. 2002 Nov;2(6):503-4.
Akahane A, Kunugi H, Tanaka H, Nanko S. Association analysis of polymorphic CGG repeat in 5' UTR of the reelin and VLDLR genes with schizophrenia. Schizophr Res. 2002 Nov 1;58(1):37-41.
Husemann J, Loike JD, Anankov R, Febbraio M, Silverstein SC. Scavenger receptors in neurobiology and neuropathology: their role on microglia and other cells of the nervous system. Glia. 2002 Nov;40(2):195-205.
Koistinaho M, Koistinaho J. Role of p38 and p44/42 mitogen-activated protein kinases in microglia. Glia. 2002 Nov;40(2):175-83.
McLaurin J, Cecal R, Kierstead ME, Tian X, Phinney AL, Manea M, French JE, Lambermon MH, Darabie AA, Brown ME, Janus C, Chishti MA, Horne P, Westaway D, Fraser PE, Mount HT, Przybylski M, St George-Hyslop P. Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat Med. 2002 Nov;8(11):1263-9.
Medina S, Martínez M, Hernanz A. Antioxidants inhibit the human cortical neuron apoptosis induced by hydrogen peroxide, tumor necrosis factor alpha, dopamine and beta-amyloid peptide 1-42. Free Radic Res. 2002 Nov;36(11):1179-84.
Suay Llopis L, Ballester Díez F. [Review of studies on exposure to aluminum and Alzheimer's disease] Rev Esp Salud Publica. 2002 Nov-Dec;76(6):645-58.
Cupello A, Rapallino MV, Tabaton M, Lunardi GL. A simple, inexpensive, and precise spectrophotometric method for evaluating the concentration of ascorbic acid in CSF samples: data from different neurological pathologies. Int J Neurosci. 2002 Nov;112(11):1337-45.
Muramatsu Y, Araki T. Glial Cells as a Target for the Development of New Therapies for Treating Parkinson's Disease. Drug News Perspect. 2002 Nov;15(9):586-590.
Rohn TT, Rissman RA, Head E, Cotman CW. Caspase Activation in the Alzheimer's Disease Brain: Tortuous and Torturous. Drug News Perspect. 2002 Nov 1;15(9):549-557.
Bidzan L, Bidzan M. [In Process Citation] Psychiatr Pol. 2002 Nov-Dec;36(6 Suppl):193-8.
Kloszewska I. [In Process Citation] Psychiatr Pol. 2002 Nov-Dec;36(6 Suppl):133-41.
Kuzuhara S. [Amyotrophic lateral sclerosis-parkinsonism-dementia complex of the Kii Peninsula of Japan] Rinsho Shinkeigaku. 2002 Nov;42(11):1073-6.
Urakami K, Nakashima K. [Corticobasal degeneration and progressive supranuclear palsy--biochemical marker] Rinsho Shinkeigaku. 2002 Nov;42(11):1162-4.
Dewachter I, Van Leuven F. Secretases as targets for the treatment of Alzheimer's disease: the prospects. Lancet Neurol. 2002 Nov 1;1(7):409-16.
Larkin M. US Alzheimer's disease prevention study under attack. Lancet Neurol. 2002 Nov;1(7):397.
Pasinetti GM, Pompl PN. Cyclo-oxygenase inhibitors and Alzheimer's: are we well ADAPTed? Lancet Neurol. 2002 Nov;1(7):403-4.
Akhondzadeh S, Noroozian M. Alzheimer's disease: Pathophysiology and pharmacotherapy. Idrugs. 2002 Nov;5(11):1062-9.
Cummings JL. 2-Deoxy-2-[18F]fluoro-D-glucose positron emission tomography in Alzheimer's diagnosis: time for technology transfer. Mol Imaging Biol. 2002 Nov;4(6):385-6.
Nagaratnam N, Gayagay G. Hypersexuality in nursing care facilities--a descriptive study. Arch Gerontol Geriatr. 2002 Nov-Dec;35(3):195-203.
Shanks MF, Venneri A. The emergence of delusional companions in Alzheimer's disease: an unusual misidentification syndrome. Cognit Neuropsychiatry. 2002 Nov;7(4):317-28.
Kamei Y, Sagara A. Neurite outgrowth promoting activity of marine algae from Japan against rat adrenal medulla pheochromocytoma cell line, PC12D. Cytotechnology. 2002 Nov;40(1-3):99-106.
Koch W, Ehrenhaft A, Griesser K, Pfeufer A, Müller J, Schömig A, Kastrati A. TaqMan systems for genotyping of disease-related polymorphisms present in the gene encoding apolipoprotein E. Clin Chem Lab Med. 2002 Nov;40(11):1123-31.
Xing Y, Higuchi K. Amyloid fibril proteins. Mech Ageing Dev. 2002 Nov;123(12):1625-36.
Citron M. Emerging Alzheimer's disease therapies: inhibition of beta-secretase. Neurobiol Aging. 2002 Nov-Dec;23(6):1017-22.
Sigurdsson EM, Wisniewski T, Frangione B. A safer vaccine for Alzheimer's disease? Neurobiol Aging. 2002 Nov-Dec;23(6):1001-8.
Nilsson LG, Nyberg L, Bäckman L. Genetic variation in memory functioning. Neurosci Biobehav Rev. 2002 Nov;26(7):841-8.
Rehman HU. Role of CRH in the pathogenesis of dementia of Alzheimer's type and other dementias. Curr Opin Investig Drugs. 2002 Nov;3(11):1637-42.
Matsubara E, Shoji M, Murakami T, Abe K, Frangione B, Ghiso J. Platelet microparticles as carriers of soluble Alzheimer's amyloid beta (sAbeta). Ann N Y Acad Sci. 2002 Nov;977:340-8.
Miyakawa T. Vascular pathology in Alzheimer's disease. Ann N Y Acad Sci. 2002 Nov;977:303-5.
Weller RO, Yow HY, Preston SD, Mazanti I, Nicoll JA. Cerebrovascular disease is a major factor in the failure of elimination of Abeta from the aging human brain: implications for therapy of Alzheimer's disease. Ann N Y Acad Sci. 2002 Nov 1;977:162-8.
Pluta R. Astroglial expression of the beta-amyloid in ischemia-reperfusion brain injury. Ann N Y Acad Sci. 2002 Nov;977:102-8.
Yamada M. Risk factors for cerebral amyloid angiopathy in the elderly. Ann N Y Acad Sci. 2002 Nov;977:37-44. ,
Lahiri DK, Kotwal GJ, Farlow MR, Sima A, Kupsky W, Sarkar FH, Sambamurti K. The role of the carboxyl-terminal fragments of amyloid precursor protein in Alzheimer's disease. Ann N Y Acad Sci. 2002 Nov;973:334-9.
Morelli L, Llovera R, Ibendahl S, Castaño EM. The degradation of amyloid beta as a therapeutic strategy in Alzheimer's disease and cerebrovascular amyloidoses. Neurochem Res. 2002 Nov;27(11):1387-99.
Howes MJ, Houghton PJ, Barlow DJ, Pocock VJ, Milligan SR. Assessment of estrogenic activity in some common essential oil constituents. J Pharm Pharmacol. 2002 Nov;54(11):1521-8.
Ji SR, Wu Y, Sui SF. Study of beta-Amyloid Peptide (Abeta40) Insertion into Phospholipid Membranes Using Monolayer Technique. Biochemistry (Mosc). 2002 Nov;67(11):1283-8.
Uchikado H, Iseki E, Tsuchiya K, Togo T, Katsuse O, Uéda K, Kato M, Kosaka K. Dementia with Lewy bodies showing advanced Lewy pathology but minimal Alzheimer pathology--Lewy pathology causes neuronal loss inducing progressive dementia. Clin Neuropathol. 2002 Nov-Dec;21(6):269-77.
de Kloet ER, Grootendorst J, Karssen AM, Oitzl MS. Gene x environment interaction and cognitive performance: animal studies on the role of corticosterone. Neurobiol Learn Mem. 2002 Nov;78(3):570-7.
Kaeriyama T, Kodama N, Shimada T, Fukumoto I. [Application of run length matrix to magnetic resonance imaging diagnosis of Alzheimer-type dementia] Nippon Hoshasen Gijutsu Gakkai Zasshi. 2002 Nov;58(11):1502-8.
De Luigi A, Pizzimenti S, Quadri P, Lucca U, Tettamanti M, Fragiacomo C, De Simoni MG. Peripheral inflammatory response in Alzheimer's disease and multiinfarct dementia. Neurobiol Dis. 2002 Nov;11(2):308-14.
Iwatsubo T. [The mechanism of A beta production and its inhibition as a therapeutic strategy for the prevention of Alzheimer's disease] Nippon Yakurigaku Zasshi. 2002 Nov;120(1):30P-33P.
Nishimoto I. ["Death and survival of neuronal cells exposed to Alzheimer's disease-relevant insults"] Nippon Yakurigaku Zasshi. 2002 Nov;120(1):11P-15P.
Athan ES, Lee JH, Arriaga A, Mayeux RP, Tycko B. Polymorphisms in the promoter of the human APP gene: functional evaluation and allele frequencies in Alzheimer disease. Arch Neurol. 2002 Nov;59(11):1793-9. , ,
Lleó A, Blesa R, Queralt R, Ezquerra M, Molinuevo JL, Peña-Casanova J, Rojo A, Oliva R. Frequency of mutations in the presenilin and amyloid precursor protein genes in early-onset Alzheimer disease in Spain. Arch Neurol. 2002 Nov;59(11):1759-63.
Riemenschneider M, Lautenschlager N, Wagenpfeil S, Diehl J, Drzezga A, Kurz A. Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment. Arch Neurol. 2002 Nov;59(11):1729-34. ,
Dewachter I, Van Leuven F. Secretases as targets for the treatment of Alzheimer's disease: the prospects Lancet Neurology. 2002 Nov 1;1(7):409-416. Full Text for Subscribers
de Leon MJ, Segal S, Tarshish CY, DeSanti S, Zinkowski R, Mehta PD, Convit A, Caraos C, Rusinek H, Tsui W. Longitudinal cerebrospinal fluid tau load increases in mild cognitive impairment. Neurosci Lett. 2002 Nov;333(3):183-6. Abstract
Brookmeyer R, Corrada MM, Curriero FC, Kawas C. Survival following a diagnosis of Alzheimer disease. Arch Neurol. 2002 Nov;59(11):1764-7. Abstract
Frishman WH. Are antihypertensive agents protective against dementia? A review of clinical and preclinical data. Heart Dis. 2002 Nov-Dec;4(6):380-6.
Prusa AR, Hengstschlager M. Amniotic fluid cells and human stem cell research: a new connection. Med Sci Monit. 2002 Nov;8(11):RA253-7.
Kukull WA, Higdon R, Bowen JD, McCormick WC, Teri L, Schellenberg GD, van Belle G, Jolley L, Larson EB. Dementia and Alzheimer disease incidence: a prospective cohort study. Arch Neurol. 2002 Nov;59(11):1737-46.
Lopez OL, Becker JT. [Treatment of Alzheimer s disease] Rev Neurol. 2002 Nov 1;35(9):850-9.
Hu XY, Zhang HY, Qin S, Xu H, Swaab DF, Zhou JN. Increased p75(NTR) expression in hippocampal neurons containing hyperphosphorylated tau in Alzheimer patients. Exp Neurol. 2002 Nov;178(1):104-11.
Chung RS, Vickers JC, Chuah MI, Eckhardt BL, West AK. Metallothionein-III inhibits initial neurite formation in developing neurons as well as postinjury, regenerative neurite sprouting. Exp Neurol. 2002 Nov;178(1):1-12.
Hogan DB, Patterson C. Progress in clinical neurosciences: Treatment of Alzheimer's disease and other dementias--review and comparison of the cholinesterase inhibitors. Can J Neurol Sci. 2002 Nov;29(4):306-14.
Maximov V, Martynenko A, Hunsmann G, Tarantul V. Mitochondrial 16S rRNA gene encodes a functional peptide, a potential drug for Alzheimer's disease and target for cancer therapy. Med Hypotheses. 2002 Nov;59(6):670-3.
Sjögren MJ, Hellström PT, Jonsson MA, Runnerstam M, Silander HC, Ben-Menachem E. Cognition-enhancing effect of vagus nerve stimulation in patients with Alzheimer's disease: a pilot study. J Clin Psychiatry. 2002 Nov;63(11):972-80.
Groth C, Nornes S, McCarty R, Tamme R, Lardelli M. Identification of a second presenilin gene in zebrafish with similarity to the human Alzheimer's disease gene presenilin2. Dev Genes Evol. 2002 Nov;212(10):486-90.
Kim HJ, Chae SC, Lee DK, Chromy B, Lee SC, Park YC, Klein WL, Krafft GA, Hong ST. Selective neuronal degeneration induced by soluble oligomeric amyloid beta-protein. FASEB J. 2002 Nov 1;
Kim YT, Downs D, Wu S, Dashti A, Pan Y, Zhai P, Wang X, Zhang XC, Lin X. Enzymic properties of recombinant BACE2. Eur J Biochem. 2002 Nov;269(22):5668-77.
Xu M, Lai MT, Huang Q, DiMuzio-Mower J, Castro JL, Harrison T, Nadin A, Neduvelil JG, Shearman MS, Shafer JA, Gardell SJ, Li YM. gamma-Secretase: characterization and implication for Alzheimer disease therapy. Neurobiol Aging. 2002 Nov-Dec;23(6):1023-30.
Gandy S. Molecular basis for anti-amyloid therapy in the prevention and treatment of Alzheimer's disease. Neurobiol Aging. 2002 Nov-Dec;23(6):1009-16.
Kono I, Mori S, Nakajima K, Kizu O, Yamada K, Sakai Y. Clinical significance of white matter changes in senile dementia of the Alzheimer type. Ann N Y Acad Sci. 2002 Nov;977:430-5.
Nagata K, Sato M, Satoh Y, Watahiki Y, Kondoh Y, Sugawara M, Box G, Wright D, Leung S, Yuya H, Shimosegawa E. Hemodynamic aspects of Alzheimer's disease. Ann N Y Acad Sci. 2002 Nov 1;977:391-402.
McLaurin J, Darabie AA, Morrison MR. Cholesterol, a modulator of membrane-associated Abeta-fibrillogenesis. Ann N Y Acad Sci. 2002 Nov;977:376-83.
Burns M, Duff K. Cholesterol in Alzheimer's disease and tauopathy. Ann N Y Acad Sci. 2002 Nov;977:367-75.
Sparks DL, Martins R, Martin T. Cholesterol and cognition: rationale for the AD cholesterol-lowering treatment trial and sex-related Differences in beta-amyloid accumulation in the brains of spontaneously hypercholesterolemic Watanabe rabbits. Ann N Y Acad Sci. 2002 Nov;977:356-66.
Bertoni-Freddari C, Fattoretti P, Delfino A, Solazzi M, Giorgetti B, Ulrich J, Meier-Ruge W. Deafferentative synaptopathology in physiological aging and Alzheimer's disease. Ann N Y Acad Sci. 2002 Nov;977:322-6.
de la Torre JC. Vascular basis of Alzheimer's pathogenesis. Ann N Y Acad Sci. 2002 Nov;977:196-215.
Ge YW, Lahiri DK. Regulation of promoter activity of the APP gene by cytokines and growth factors: implications in Alzheimer's disease. Ann N Y Acad Sci. 2002 Nov;973:463-7.
Russo C, Dolcini V, Salis S, Venezia V, Violani E, Carlo P, Zambrano N, Russo T, Schettini G. Signal transduction through tyrosine-phosphorylated carboxy-terminal fragments of APP via an enhanced interaction with Shc/Grb2 adaptor proteins in reactive astrocytes of Alzheimer's disease brain. Ann N Y Acad Sci. 2002 Nov;973:323-33.
Kotwal GJ, Lahiri DK, Hicks R. Potential intervention by vaccinia virus complement control protein of the signals contributing to the progression of central nervous system injury to Alzheimer's disease. Ann N Y Acad Sci. 2002 Nov;973:317-22.
Tabira T. [Progress in developing anti-Alzheimer drugs] Nippon Yakurigaku Zasshi. 2002 Nov;120(1):34P-36P.
Nabeshima T, Noda Y, Kamei H. [Anti-dementia drugs for Alzheimer disease in present and future] Nippon Yakurigaku Zasshi. 2002 Nov;120(1):24P-29P.
Paleacu D, Mazeh D, Mirecki I, Even M, Barak Y. Donepezil for the treatment of behavioral symptoms in patients with Alzheimer's disease. Clin Neuropharmacol. 2002 Nov-Dec;25(6):313-7.
Richard IH, Justus AW, Greig NH, Marshall F, Kurlan R. Worsening of motor function and mood in a patient with Parkinson's disease after pharmacologic challenge with oral rivastigmine. Clin Neuropharmacol. 2002 Nov-Dec;25(6):296-9.
Blass JP. Alzheimer's disease and Alzheimer's dementia: distinct but overlapping entities. Neurobiol Aging. 2002 Nov-Dec;23(6):1077-84.
Lemere CA, Spooner ET, Leverone JF, Mori C, Clements JD. Intranasal immunotherapy for the treatment of Alzheimer's disease: Escherichia coli LT and LT(R192G) as mucosal adjuvants. Neurobiol Aging. 2002 Nov-Dec;23(6):991-1000.
Trojanowski JQ. "Emerging Alzheimer's disease therapies: focusing on the future". Neurobiol Aging. 2002 Nov-Dec;23(6):985-90.
Mori S. Responses to donepezil in Alzheimer's disease and Parkinson's disease. Ann N Y Acad Sci. 2002 Nov;977:493-500.
Goldsmith HS. Treatment of Alzheimer's disease by transposition of the omentum. Ann N Y Acad Sci. 2002 Nov;977:454-67.
Watanabe T, Akiguchi I, Yagi H, Onishi K, Kawasaki T, Shiino A, Inubushi T. Proton magnetic resonance spectroscopy and white matter hyperintensities on magnetic resonance imaging in patients with Alzheimer's disease. Ann N Y Acad Sci. 2002 Nov;977:423-9.
Wu CC, Mungas D, Eberling JL, Reed BR, Jagust WJ. Imaging Interactions between Alzheimer's disease and cerebrovascular disease. Ann N Y Acad Sci. 2002 Nov;977:403-10.
Friedland RP. Lipid metabolism, epidemiology, and the mechanisms of Alzheimer's disease. Ann N Y Acad Sci. 2002 Nov;977:387-90.
Dantoine TF, Drouet M, Debord J, Merle L, Cogne M, Charmes JP. Paraoxonase 1 192/55 gene polymorphisms in Alzheimer's disease. Ann N Y Acad Sci. 2002 Nov;977:239-44. ,
Wakutani Y, Kowa H, Kusumi M, Yamagata K, Wada-Isoe K, Adachi Y, Takeshima T, Urakami K, Nakashima K. Genetic analysis of vascular factors in Alzheimer's disease. Ann N Y Acad Sci. 2002 Nov;977:232-8. ,
Mitsui S, Okui A, Uemura H, Mizuno T, Yamada T, Yamamura Y, Yamaguchi N. Decreased cerebrospinal fluid levels of neurosin (KLK6), an aging-related protease, as a possible new risk factor for Alzheimer's disease. Ann N Y Acad Sci. 2002 Nov;977:216-23. ,
Ishizuka K, Kimura T, Yoshitake J, Akaike T, Shono M, Takamatsu J, Katsuragi S, Kitamura T, Miyakawa T. Possible assessment for antioxidant capacity in Alzheimer's disease by measuring lymphocyte heme oxygenase-1 expression with real-time RT-PCR. Ann N Y Acad Sci. 2002 Nov;977:173-8.
Nakata Y, Shiga K, Yoshikawa K, Mizuno T, Mori S, Yamada K, Nakajima K. Subclinical brain hemorrhages in Alzheimer's disease: evaluation by magnetic resonance T2*-weighted images. Ann N Y Acad Sci. 2002 Nov;977:169-72.
Ozawa K, Tomiyama T, Maat-Schieman ML, Roos RA, Mori H. Enhanced Abeta40 deposition was associated with increased Abeta42-43 in cerebral vasculature with Dutch-type hereditary cerebral hemorrhage with amyloidosis (HCHWA-D). Ann N Y Acad Sci. 2002 Nov;977:149-54.
No comments:
Post a Comment